Tesamorelin Dosage for Fat Loss: Clinical Protocols & Results (2026)

The distinction matters clinically. Exogenous GH (somatropin) delivers a fixed dose that bypasses the pituitary entirely. This often raises IGF-1 levels above the physiological range, increasing the risk of edema, joint pain, carpal tunnel syndrome, and insulin resistance.

Tesamorelin stimulates endogenous GH release, which means the pituitary retains its negative feedback loop. When GH and IGF-1 rise, somatostatin signals the pituitary to slow down. This self-regulating mechanism keeps levels closer to the physiological ceiling (Dhillon, Drugs 2011).

For researchers comparing growth hormone secretagogues, our peptide stacking guide covers how tesamorelin fits alongside other GH peptides.

Two pivotal Phase 3 trials established the efficacy of the 2 mg dose. Both enrolled HIV-positive adults with excess abdominal fat (lipodystrophy), as measured by CT scan at baseline.

Trial 1 (TH9507-CT-SEROST-0502): 412 participants randomized to tesamorelin 2 mg or placebo for 26 weeks (Falutz et al., NEJM 2007):

Trial 2 (TH9507-CT-SEROST-0504): 404 participants, same design (Falutz et al., JAIDS 2010):

Two things stand out. First, tesamorelin selectively targets visceral fat while preserving limb fat and lean mass. Second, the visceral fat reduction was consistent across both trials: roughly 15 to 18% in 26 weeks. For a peptide that does not require caloric restriction, those numbers are clinically significant.

An open-label extension followed participants for an additional 26 weeks (52 weeks total). Among those who continued tesamorelin, visceral fat reduction was maintained. Among those switched from tesamorelin to placebo at week 26, visceral fat returned to near-baseline levels within 3 months (Falutz et al., JAIDS 2010).

This finding has practical implications: tesamorelin's fat-reducing effect depends on continued use. Stopping the peptide leads to visceral fat reaccumulation. The data suggest ongoing or cyclical use is necessary to maintain results.

This rebound pattern is consistent across GH-based therapies. Growth hormone increases lipolysis actively; when the stimulus is removed, the metabolic environment returns to its prior state. Planning for this reality is essential, and we cover cycling strategies in detail below.

Outside the HIV lipodystrophy indication, clinicians at anti-aging and optimization clinics prescribe tesamorelin off-label for general visceral fat reduction. The dose remains 2 mg/day in most protocols, consistent with the FDA-approved regimen.

Some practitioners use a lower dose of 1 mg/day as a starting point for patients new to GH peptides, particularly those with lower body weight or those concerned about cost. No controlled trial has evaluated 1 mg/day head-to-head against 2 mg/day for fat loss. The available pharmacokinetic data suggest that 1 mg produces a smaller GH pulse, so the lipolytic effect is proportionally reduced (Stanley & Bhatt, Expert Opin Pharmacother 2012).

Use the peptide cost calculator to compare the per-month expense of different dosing protocols.

Inject in the morning on an empty stomach for optimal GH response. Growth hormone release is blunted by elevated blood glucose and insulin. Food, especially carbohydrates, raises both. Injecting fasted ensures the pituitary responds maximally to the GHRH stimulus.

Wait at least 15 to 30 minutes after injection before eating. This window allows the GH pulse to peak. Eating immediately after injection raises insulin, which opposes GH secretion and partially negates the lipolytic effect.

The Egrifta prescribing information specifies injection "before breakfast" for this reason. While evening injection is technically possible, the largest natural GH pulse occurs during the first hours of sleep. Adding a morning tesamorelin pulse creates a second daily GH peak, maximizing the total daily GH exposure without interfering with nocturnal physiology.

The FDA-approved injection site is the abdomen. Inject at least 2 inches from the navel. Rotate between different abdominal quadrants each day to prevent injection site reactions and lipohypertrophy.

Standard rotation pattern for daily injections:

• Day 1: Upper right abdomen
• Day 2: Lower right abdomen
• Day 3: Upper left abdomen
• Day 4: Lower left abdomen
• Day 5: Repeat cycle

Avoid injecting into scar tissue, bruises, or areas of skin irritation. The needle gauge for tesamorelin is typically 29 to 31 gauge, the same insulin syringes used for other subcutaneous peptides.

The most common off-label protocol:

Twelve weeks provides roughly half the visceral fat reduction seen at 26 weeks in the Phase 3 trials. The off period allows the pituitary to reset and prevents potential desensitization of GHRH receptors. In practice, most users report retaining a portion of the fat loss during the off period, particularly if they maintain a caloric deficit and regular exercise.

This mirrors the Phase 3 trial duration and produces the full 15 to 18% visceral fat reduction. It is the best-studied timeframe.

The longer off period (8 to 12 weeks) accounts for the fact that the 52-week extension data showed fat reaccumulation begins within weeks of stopping. A longer active phase followed by a generous off period provides the best balance between results and recovery.

The peptide half-life tracker can help you understand how quickly tesamorelin clears your system after the last injection.

Some practitioners recommend injecting Monday through Friday and resting on weekends. The rationale: reducing total weekly exposure by approximately 30% while maintaining most of the lipolytic stimulus.

No clinical trial has tested this specific schedule. The pharmacokinetic rationale is tenuous: tesamorelin has a half-life of about 26 minutes, so the peptide itself clears rapidly regardless. The effect depends on the downstream GH pulse, which lasts several hours. Missing two days per week likely reduces cumulative GH exposure meaningfully.

This protocol is reasonable for cost management but probably sacrifices some efficacy. If budget is the primary constraint, a lower daily dose (1 mg/day, 7 days per week) may produce more consistent results than an interrupted schedule.

CJC-1295 (with DAC) is a modified GHRH analog with a dramatically longer half-life (5 to 8 days) due to its Drug Affinity Complex. It is often combined with ipamorelin, a growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors rather than GHRH receptors.

The critical advantage of tesamorelin is evidence quality. Its visceral fat reduction was measured by CT scan in randomized, placebo-controlled trials with hundreds of participants. CJC-1295/ipamorelin has anecdotal support and small studies but nothing approaching that level of evidence (Ionescu & Bhatt, Expert Opin Biol Ther 2015).

The critical advantage of CJC-1295/ipamorelin is cost. It runs roughly one-third the monthly price of tesamorelin at research-grade pricing. For users prioritizing affordability over evidence certainty, the combination is a practical alternative.

Sermorelin is the first 29 amino acids of natural GHRH. It was FDA-approved for pediatric growth hormone deficiency (brand name Geref) but was discontinued in 2008 for commercial reasons, not safety concerns.

Sermorelin's shorter half-life means it produces a weaker GH pulse per injection. The hexenoic acid modification on tesamorelin is specifically what gives it the pharmacokinetic edge. For fat loss, tesamorelin is the stronger choice when budget allows. For general anti-aging and GH optimization on a budget, sermorelin remains popular in clinical practice.

For dosing details on other GH secretagogues, see our guides on hexarelin dosage and MOTS-c peptide dosage.

Tesamorelin and GLP-1 agonists reduce body fat through entirely different pathways. Comparing them directly is like comparing a scalpel to a sledgehammer: both remove material, but the precision and mechanism are unrelated.

Tesamorelin does not cause significant total weight loss. It reduces visceral fat specifically while preserving lean mass. GLP-1 agonists produce large-scale weight loss that includes both fat and some lean tissue.

For individuals whose primary concern is visceral fat around the organs (the metabolically active fat linked to cardiovascular disease and insulin resistance) rather than total body weight, tesamorelin addresses the specific problem. For those who need substantial overall weight reduction, GLP-1 agonists or triple agonists like retatrutide are more appropriate. Some practitioners combine both approaches. For peptide combination strategies, see the peptide stacking guide.

Always use bacteriostatic water for multi-dose vials. The benzyl alcohol preservative prevents bacterial growth and allows the reconstituted solution to last 28 to 30 days when refrigerated. Sterile water contains no preservative and must be used within 24 to 48 hours. For sourcing, see where to buy bacteriostatic water for injection.

1. 1.Clean the rubber stoppers on both the tesamorelin vial and the bacteriostatic water vial with alcohol swabs. Allow to dry.
2. 2.Draw your chosen volume of bacteriostatic water into the syringe. For a 2 mg vial, use 0.5 mL for a concentration of 4 mg/mL (convenient for a 2 mg dose = 0.5 mL). For a 5 mg vial, use 1 mL for a concentration of 5 mg/mL.
3. 3.Insert the needle into the tesamorelin vial at a slight angle. Let the water flow slowly down the inside wall of the glass. Never spray directly onto the lyophilized cake.
4. 4.Swirl the vial gently in a circular motion. Do not shake. Shaking creates foam, denatures the peptide, and reduces potency.
5. 5.Wait until fully dissolved. The solution should be clear and colorless. If you see particles, refrigerate for 15 minutes and swirl again.
6. 6.Label the vial with the reconstitution date and concentration.
7. 7.Store immediately at 2 to 8 degrees Celsius (standard refrigerator temperature).

Use the reconstitution calculator to determine exact volumes for any vial size.

With a 2 mg vial reconstituted in 0.5 mL bacteriostatic water (4 mg/mL):

With a 5 mg vial reconstituted in 1 mL bacteriostatic water (5 mg/mL):

The 5 mg vial offers better value per milligram, but at the standard 2 mg/day dose, a single vial lasts only 2.5 days. This means frequent reconstitution. Some users reconstitute several vials at once and rotate through them during the week. For storage guidelines and shelf life of reconstituted peptides, see how long do reconstituted peptides last and does bacteriostatic water need to be refrigerated.

The most frequently reported adverse events from the Phase 3 trials (Falutz et al., NEJM 2007; Dhillon, Drugs 2011):

Injection site reactions are the most common complaint. They are typically mild: redness, itching, or a small bump at the injection site that resolves within hours. Rotating injection sites daily minimizes this issue.

Joint pain and edema are growth hormone-mediated effects. They occur because GH increases fluid retention and stimulates tissue growth. These effects are dose-dependent and generally resolve within the first 4 to 6 weeks as the body adapts. If persistent, they may indicate IGF-1 levels above the desired range.

Tesamorelin raises IGF-1 levels by an average of 81 ng/mL over 26 weeks. The prescribing information recommends measuring IGF-1 at baseline and during treatment. If IGF-1 exceeds 3 standard deviations above the age-adjusted mean, discontinuation should be considered (Egrifta SV Prescribing Information, 2023).

In practice, most anti-aging practitioners check IGF-1 at baseline, 6 weeks, and 12 weeks. A target IGF-1 range of 200 to 300 ng/mL for adults under 50 (or the upper third of the age-adjusted reference range) is commonly used.

Elevated IGF-1 is not inherently dangerous in the short term, but chronically elevated levels are associated with increased cancer risk in epidemiological studies. This is why cycling tesamorelin (rather than continuous indefinite use) is the preferred approach for off-label fat loss protocols.

Tesamorelin is contraindicated in the following populations per the FDA label:

• Active malignancy: GH and IGF-1 can promote tumor growth. Do not use tesamorelin if you have an active cancer diagnosis.
• Pregnancy: Tesamorelin is classified as pregnancy category X. It has demonstrated fetal harm in animal studies.
• Disruption of the hypothalamic-pituitary axis: Conditions such as pituitary surgery, radiation, or head trauma may prevent the pituitary from responding to GHRH stimulation, rendering tesamorelin ineffective.
• Known hypersensitivity: Allergy to tesamorelin or mannitol (an excipient in the formulation).

Additionally, patients with a history of pituitary tumors should avoid tesamorelin. For a complete overview of peptide contraindications and drug interactions, see the peptide safety guide.

A randomized, double-blind trial of 61 HIV-positive patients with NAFLD and hepatic steatosis found that tesamorelin 2 mg/day for 12 months significantly reduced liver fat content (measured by MRI spectroscopy) and prevented progression of hepatic fibrosis (Stanley et al., Ann Intern Med 2014).

Liver fat decreased by 37% in the tesamorelin group versus an increase of 7% in the placebo group. The number of patients with hepatic steatosis resolution (liver fat below 5%) was 35% in the tesamorelin group versus 4% in placebo.

This finding is significant because visceral fat and liver fat are metabolically linked. Reducing visceral adiposity improves hepatic lipid metabolism, potentially slowing or reversing fatty liver disease.

Pooled analysis of the Phase 3 trials showed that tesamorelin reduced triglycerides by approximately 50 mg/dL and improved the ratio of trunk fat to limb fat, a surrogate marker for cardiometabolic risk (Falutz et al., JAIDS 2010).

A subsequent study found that 12 months of tesamorelin reduced carotid intima-media thickness (cIMT), an established predictor of atherosclerotic cardiovascular disease, in HIV-positive individuals with increased visceral fat (Fourman et al., J Clin Endocrinol Metab 2020).

These findings suggest that tesamorelin's visceral fat reduction translates into meaningful cardiovascular risk reduction, though no trial has yet measured hard cardiovascular endpoints (heart attack, stroke).

An unexpected finding emerged from a separate line of research: tesamorelin may improve cognitive function in older adults. A randomized, double-blind trial of 152 cognitively normal adults aged 55 to 87 found that tesamorelin 1 mg/day for 20 weeks improved executive function, verbal memory, and processing speed compared to placebo (Baker et al., Arch Neurol 2012).

The mechanism is likely IGF-1-mediated. IGF-1 receptors are abundant in the hippocampus and prefrontal cortex, regions critical for memory and executive function. Whether these cognitive benefits are sustained with longer treatment or translate into reduced dementia risk remains unknown.

Never freeze reconstituted tesamorelin. Freezing can cause the peptide to denature and lose potency. Protect from light and temperature fluctuations. For comprehensive peptide storage protocols, see how to store peptides and how long does bacteriostatic water last.

Egrifta SV (the commercial product) is available by prescription and typically covered by insurance for HIV lipodystrophy. Without insurance, the retail price exceeds $1,000 per month.

Research-grade tesamorelin is available from peptide suppliers at lower cost, though quality varies significantly between vendors. Third-party testing (HPLC purity and mass spectrometry verification) is essential when purchasing from research suppliers. For guidance on evaluating peptide vendors, see where to buy peptides 2026. Note that the FDA peptide crackdown 2026 has affected the availability and legality of certain research peptides.

At 2 mg/day, a 30-day supply of research-grade tesamorelin ranges from $200 to $500 depending on the vendor and vial size. Several strategies reduce cost:

• Buy larger vials. A single 10 mg vial is typically cheaper per milligram than five 2 mg vials.
• Cycle rather than use continuously. A 12-week cycle with a 4-week off period reduces annual peptide consumption by approximately 25%.
• Consider the 1 mg/day protocol. If budget is the limiting factor, 1 mg/day halves the cost while still producing some GH elevation and lipolytic effect.
• Compare using the peptide cost calculator. Input your dose, frequency, and vial size to see the true monthly and annual cost.

For related peptide options at different price points, compare with follistatin 344 dosage and GHK-Cu injection dosage.

Injecting tesamorelin on an empty stomach triggers a GH pulse within 15 to 30 minutes. Growth hormone mobilizes fatty acids from visceral adipose stores into the bloodstream. Performing low-to-moderate intensity cardiovascular exercise during this window burns those mobilized fatty acids before they are re-esterified and stored again.

The combination of fasted tesamorelin injection followed by 30 to 45 minutes of walking, cycling, or light jogging is the most commonly recommended protocol among practitioners who prescribe tesamorelin for body composition. No controlled trial has tested this specific combination, but the physiological rationale is sound: GH mobilizes fat, exercise oxidizes it.

Avoid high-intensity exercise immediately after injection. Intense exercise raises cortisol, which opposes GH-mediated lipolysis and promotes visceral fat storage (Djurhuus et al., Am J Physiol Endocrinol Metab 2004). Moderate intensity is the sweet spot.

Tesamorelin does not suppress appetite. Unlike GLP-1 agonists, you will not feel less hungry. This means dietary discipline remains entirely your responsibility.

A moderate caloric deficit (300 to 500 calories below maintenance) amplifies tesamorelin's fat-reducing effect. The peptide preferentially mobilizes visceral fat; a caloric deficit ensures those mobilized fatty acids are burned rather than redistributed.

Protein intake is critical. Tesamorelin preserves and may slightly increase lean body mass, but only if sufficient amino acids are available. Aim for 1.6 to 2.2 g of protein per kilogram of body weight daily, consistent with current recommendations for body recomposition.

Minimize refined carbohydrates and sugar, especially in the morning after injection. Insulin spikes counteract GH signaling. A protein-and-fat breakfast (consumed 30 or more minutes after injection) maintains the favorable hormonal environment.

Growth hormone secretion peaks during slow-wave sleep (deep sleep). Tesamorelin adds a morning GH pulse; you want the nocturnal pulse to remain strong. Poor sleep blunts nighttime GH release, reducing the total daily GH exposure.

Practical sleep priorities for tesamorelin users:

• 7 to 9 hours per night. Consistently.
• Consistent sleep and wake times. Circadian rhythm regularity supports GH pulsatility.
• Avoid late-night eating. Insulin and blood glucose suppress nocturnal GH release.
• Limit alcohol. Alcohol disrupts slow-wave sleep architecture and reduces GH secretion by up to 75% (Van Cauter et al., Lancet 1999).

For guidance on peptides that support gut health and overall recovery alongside a fat loss protocol, see peptides for gut health.